A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia

for the MEM-MD-29 Study Group, Lieberman, Jeffrey A, Papadakis, Kelly, Csernansky, John, Litman, Robert, Volavka, Jan, Jia, Xinwei Daniel, Gage, Allyson·2009·Neuropsychopharmacology
DOI 10.1038/npp.2008.200

Cited by (161)

Items 101–161 of 161

  1. In silico molecular docking analysis for potential anti-Alzheimer's compounds from the methanolic leaf extract of Erythroxylum monogynum using Gas chromatography–mass spectrometry
    Paranthaman Subash, Kareti Srinivasa Rao · 2021 · Journal of Saudi Chemical Society
  2. Tackling Negative Symptoms of Schizophrenia with Memantine
    Antonios Paraschakis · 2014 · Case Reports in Psychiatry
  3. Symptomatic thinking: the current state of Phase III and IV clinical trials for cognition in schizophrenia
    John C. Talpos · 2017 · Drug Discovery Today
  4. Schizophrenia and Related Psychoses
    2021 · Wiley eBooks
  5. The Effect of Memantine Versus Folic Acid on Cognitive Impairment in Patients with Schizophrenia: A Randomized Clinical Trial
    Seyed Ahmad Hosseini, Zahra Sepehrmanesh, Hamidreza Gilasi, Fatemeh Sadat Ghoreishi · 2023 · Iranian Journal of Psychiatry
  6. Augmentation Strategies for Partial or Non-responders to Clozapine in Patients with Schizophrenia: A Bayesian Network Meta-analysis of Randomized Controlled Trials
    Archana Mishra, Rituparna Maiti, Biswa Ranjan Mishra, Anand Srinivasan · 2023 · Clinical Psychopharmacology and Neuroscience
  7. Study of the Effect of Memantine on Negative Sign in Patients with Schizophrenia and Schizoaffective Disorders.
    Maria Tavakoli Ardakani, Hamide Abbaspour, Abdollah Farhadi Nasab, Azadeh Mazaheri Meybodi, Ali Kheradmand · 2018 · Europe PMC (PubMed Central)
  8. Cognitive Enhancement in Schizophrenia and Related Disorders
    Matcheri S. Keshavan, Shaun M. Eack · 2019 · Cambridge University Press eBooks
  9. Are NMDA receptor antagonists beneficial in the treatment of schizophrenia?
    Seong S. Shim, Rashid N Nadeem · 2014 · Journal of Psychiatric Research
  10. Efficacy of Zinc Sulfate as an Add-on Therapy to Risperidone versus Risperidone Alone in Patients With Schizophrenia: A Double-Blind Randomized Placebo-Controlled Trial
    Mehran Mortazavi, Davood Farzin, Mehran Zarhghami, Seyed Hamzeh Hosseini, Parisa Mansoori, Gholamreza Nateghi · 2015 · Iranian Journal of Psychiatry and Behavioral Sciences
  11. Current and future treatment modalities in schizophrenia: novel antipsychotic drugs and cognitive therapy
    Peter J. McKenna, Ann Margaret Mortimer · 2013 · Expert Review of Neurotherapeutics
  12. Targeting Epigenetics Signaling with Curcumin: A Transformative Drug Lead in Treatment of Schizophrenia?
    Simon Chiu, Michel Woodbury Farina, Kristen J. Terpstra, Vladimir Badmaev, Zack Z. Cernovsky, Yves Bureau, Jerry Jirui, Hana Raheb, Mariwan Husn, John Copen et al. · 2017 · Journal of Clinical Epigenetics
  13. Treatment of Clozapine Nonresponders
    Sandeep Grover, Swapnajeet Sahoo · 2019 · Current Treatment Options in Psychiatry
  14. Neurocognition and Treatment Outcomes in Schizophrenia
    Juan L. Molina, Ming T. Tsuang · 2020 · Springer eBooks
  15. Augmentation of clozapine with dextromethorphan in treatment-resistant schizophrenia: A randomized, group sequential adaptive design, controlled clinical trial
    Naveen Chandrashekar Hegde, Biswa Ranjan Mishra, Debadatta Mohapatra, Anand Srinivasan, Rituparna Maiti · 2026 · Asian Journal of Psychiatry
  16. Augmentation Therapies as Treatments for Coexisting Somatic Problems in Schizophrenia—A Systematic Review
    W. Dróżdż, Michał Wiciński, Anna Maria Szota, Monika Szambelan, Izabela Radajewska, Igor Popławski, Paweł Wojciechowski · 2023 · Journal of Clinical Medicine
  17. Application of Real-World Data and the REWARD Framework to Detect Unknown Benefits of Memantine and Identify Potential Disease Targets for New NMDA Receptor Antagonists
    David M. Kern, Maria Soledad Cepeda, Christopher M. Flores, Gayle M. Wittenberg · 2021 · CNS Drugs
  18. The Brain That Builds Itself
    Matcheri S. Keshavan, Shaun M. Eack · 2019 · Cambridge University Press eBooks
  19. New Therapeutic Strategies for Resistance to Clozapine and Treatment-Resistant Schizophrenia
    Juliano Santos Souza, Mônica Kayo, Jorge Henna Neto, Hélio Elkis, P.F. Buckley · 2010 · Advances in biological psychiatry
  20. The role of NMDA receptor antagonists, amantadine and memantine, in schizophrenia treatment: a systematic review
    Bruno Terra Junho, Victor Fernandes de Oliveira · 2019 · Archives of Clinical Psychiatry (São Paulo)
  21. Brain Protection in Neuropsychiatric Disorders: Past, Present and Future Challenges
    Ehud Susser, Michael S. Ritsner · 2010 · Springer eBooks
  22. Şizofrenide Kombinasyon Tedavileri
    Vesile Altınyazar, Nevzat Yüksel · 2011 · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology
  23. Critics on "Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study"
    Chi‐Un Pae · 2013 · Psychiatry Investigation
  24. Memantine as an Adjuvant in Cognitive Symptoms of Schizophrenia with a Chronic Course: A Follow-up Study
    Md Abdul Salaam, Geethanjali Koyilada, Raj Kiran Donthu · 2025 · Indian Journal of Psychological Medicine
  25. Ketamine for negative and depressive symptoms in schizophrenia: the evidence so far
    Cornelia Diendorfer, C. Bum, Ana Weidenauer, Ulrich Sauerzopf, Lucie Bartova, Irena Dajic, L. Müller, Dan Rujescu, Nicole Praschak-Rieder, Matthäus Willeit · 2026 · Frontiers in Psychiatry
  26. Common molecular signatures: the role of BDNF, melatonin, and orexin in the ASD-schizophrenia continuum
    Nahi Sabih Alruwaili, Hayder Mutter Al-Kuraishy, Ali Ismail Al-Gareeb, Mustafa M Shokr, Neda M. Bogari, Suhair Alhelfawi, Mubarak Alruwaili, Gaber El‐Saber Batiha · 2026 · Molecular Biology Reports
  27. Symptômes négatifs de la schizophrénie : nouvelles approches pharmacologiques
    M.-A. Lodovighi, Alfredo Palomba, Raoul Belzeaux-R, M. Adida, Jean‐Michel Azorin · 2015 · L Encéphale
  28. Memantine: procognitive and antinegative effects in mental illness (a literature review)
    Dmitry V. Romanov, Polina G. Iuzbashian · 2020 · Neurology neuropsychiatry Psychosomatics
  29. Memantine for the Treatment of Primary Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Controlled Trials
    Houlin Hong, Jack Donlon, Martin Schaefer, Susanne Sarkar, Dragana Bugarski‐Kirola, Mujeeb Uddin Shad, Wei Hou, Matthias Kirschner, Sajoy Purathumuriyil Varghese, Ludmil V. Mitrev et al. · 2025 · Clinical Drug Investigation
  30. ¿Estamos estudiando y tratando correctamente la esquizofrenia?
    Neal R. Swerdlow · 2011 · Psiquiatría Biológica
  31. Behandlung der Schizophrenie
    Thomas Messer, Cordula Tiltscher, Max Schmauß · 2015 · Springer eBooks
  32. Applications of Neurophysiological Biomarkers in CNS Drug Development: Focus on Psychoses
    Yash B. Joshi, Melissa A. Tarasenko, Gregory A. Light · 2019 · Handbook of behavioral neuroscience
  33. Psychopharmacological Approaches, Cognitive Enhancement, and Brain Stimulation
    Matcheri S. Keshavan, Shaun M. Eack · 2019 · Cambridge University Press eBooks
  34. The Magic Shotgun: Does It Fit the Clinician and Will It Point at Schizophrenia?
    Ann Margaret Mortimer · 2011 · Springer eBooks
  35. Schizophrenia and Related Psychoses
    2025 · Wiley eBooks
  36. Assessment and treatment of cognitive impairment and related features
    Philip D. Harvey · 2013 · Cambridge University Press eBooks
  37. Neue Ansätze in der pharmakologischen Behandlung der Schizophrenie
    Falko Biedermann, W. Wolfgang Fleischhacker · 2011 · Psychiatrie und Psychotherapie
  38. Excitatory amino acid transporter expression and regulation in prefrontal cortex in schizophrenia
    Déborah Bauer · 2010 · Deep Blue (University of Michigan)
  39. Pharmakotherapie von Gedächtnisstörungen
    Gerhard Gründer · 2013 · Springer eBooks
  40. Prise en soins de la schizophrénie chez la personne âgée
    Nathalie Trächsel, A von · 2011 · Schweizer Archiv für Neurologie und Psychiatrie
  41. Treatment-Resistant Schizophrenia: Assessment and Management
    Sandeep Grover, Harsh Garekar, Anisha Agarwal · 2018 · Springer eBooks
  42. Evaluation of the Efficacy and Safety of Adding Pregabalin to Antipsychotic Treatment in Patients With Chronic Schizophrenia: A Double-blind Placebo-controlled Clinical Trial
    Samaneh Farnia, Elham Mahtiyan, Mehran Zarghami, Parisa Eslami Parkoohi, Aida Emadian, Narjes Hendouei · 2021 · Iranian Journal of Psychiatry and Clinical Psychology
  43. Computer-based Approaches to Cognitive Enhancement
    Matcheri S. Keshavan, Shaun M. Eack · 2019 · Cambridge University Press eBooks
  44. Cognition and Its Impairment in Schizophrenia and Related Psychotic Disorders
    Matcheri S. Keshavan, Shaun M. Eack · 2019 · Cambridge University Press eBooks
  45. Who Responds Best? Predictors and Moderators of Cognitive Enhancement
    Matcheri S. Keshavan, Shaun M. Eack · 2019 · Cambridge University Press eBooks
  46. Individual and Group Approaches to Cognitive Enhancement
    Matcheri S. Keshavan, Shaun M. Eack · 2019 · Cambridge University Press eBooks
  47. Non-Invasive Brain Stimulation Modulates GABAergic Activity In Neurofibromatosis 1
    Shruti Garg, Steve Williams, JeYoung Jung, Gorana Pobric, Tulika Nandi, Ben Lim, Grace Vassallo, Jonathan Green, D. Gareth Evans, Charlotte Jane Stagg et al. · 2021 · Research Square
  48. Research in Cognitive Enhancement
    Matcheri S. Keshavan, Shaun M. Eack · 2019 · Cambridge University Press eBooks
  49. Approaches to Assessment and Monitoring Treatment Response
    Matcheri S. Keshavan, Shaun M. Eack · 2019 · Cambridge University Press eBooks
  50. Choosing the Right Treatment for the Right Patient
    Matcheri S. Keshavan, Shaun M. Eack · 2019 · Cambridge University Press eBooks
  51. Getting Ready for Cognitive Enhancement
    Matcheri S. Keshavan, Shaun M. Eack · 2019 · Cambridge University Press eBooks
  52. Cognitive Enhancement
    Matcheri S. Keshavan, Shaun M. Eack · 2019 · Cambridge University Press eBooks
  53. Glossary
    Matcheri S. Keshavan, Shaun M. Eack · 2019 · Cambridge University Press eBooks
  54. Foreword
    Til Wykes Dame · 2019 · Cambridge University Press eBooks
  55. References
    2019 · Cambridge University Press eBooks
  56. Preface
    Matcheri S. Keshavan, Shaun M. Eack · 2019 · Cambridge University Press eBooks
  57. Non-invasive Brain Stimulation Modulates GABAergic Activity in Neurofibromatosis 1
    Shruti Garg, Steve Williams, JeYoung Jung, Gorana Pobric, Tulika Nandi, Ben Lim, Grace Vassallo, Jonathan Green, D. Gareth Evans, Charlotte Jane Stagg et al. · 2021 · Research Square
  58. Index
    Matcheri S. Keshavan, Shaun M. Eack · 2019 · Cambridge University Press eBooks
  59. New Strategies to Improve Cognitive Symptom Domain in the Treatment of Schizophrenia
    Stefano Barlati, Cassandra Ariu, Andrea Garozzo, Antonio Vita · 2022 · Springer eBooks
  60. Accessory Effect of Memantine on Negative Symptoms of Schizophrenia Patients: A Controlled Study
    乘洋 刘 · 2023 · Advances in Clinical Medicine
  61. The Early-Onset Efficacy of Memantine Adjunctive Treatment for Depressive Symptoms: A Systematic Review and Updated Meta-Analysis
    Liying Dong, Fugang Luo, Ruo-Bing Qi, Pan Yan, Shu-Qi Wang, Shengdong Wang, Mingfen Song · 2023 · SSRN Electronic Journal